Check the FEV1 for all adult smokers, even patients without respiratory symptoms.
P. Enright
DOI: https://doi.org/10.4104/pcrj.2010.00037
2010-05-28
Primary Care Respiratory Journal
Abstract:Clinical practice guidelines (CPGs) usually become more complicated over time, but new evidence – including a study published in this issue of the PCRJ – makes COPD casefinding easier and much more efficient. The forced expiratory volume in one second (FEV1) should be measured using an inexpensive pocket spirometer for all smokers aged 40 and over, regardless of the presence or absence of respiratory symptoms. Only the one patient in eight with a low FEV1 then needs preand post-bronchodilator spirometry to confirm clinically-important COPD. More than 30,000 spirometry tests were done by 440 Swiss GPs for their currentlysmoking patients, as recommended by many CPGs. Of those with good quality spirometry and short respiratory questionnaires, about 13% had clinically-important COPD for which inhaler treatment might be considered (a low FEV1/forced vital capacity (FVC) ratio, and FEV1 below 65% predicted), but these patients were no more likely than the others to report cough, phlegm, wheeze, or dyspnoea. As confirmed by other investigators, the COPD screening questionnaires developed and advertised by drug manufacturers provided no value in primary care settings beyond knowledge of smoking status and age. These questionnaires may help to promote “COPD awareness” (and increase inhaler sales) when published in the popular media, but some smokers without worrisome respiratory symptoms may falsely conclude that they are not at increased risk of having COPD. About a quarter of adult smokers in the Swiss study reported that they became short of breath when hurrying or walking up a slight hill. This corresponds to Grade 2 on the Medical Research Council (MRC) dyspnoea scale. However, the same percentage of Swiss patients reported this level of dyspnoea when spirometry was entirely normal or when spirometry showed moderate to severe airway obstruction. This suggests that performing spirometry only for patients who report dyspnoea on exertion is not helpful for detecting COPD. Of course, smokers who have slowly developed very severe COPD (FEV1 below about 1 litre) are likely to report having to stop to catch their breath after walking a few minutes on level ground (MRC Grade 4), but only 1% of adult smokers had this degree of impairment. Most of the Swiss GPs found it difficult to obtain diagnostic-quality spirometry tests more than 80% of the time. Only about 40% of the tests met relaxed quality goals (at least three acceptable manoeuvres with the highest two FEV1s matching within 200mL). The standardised spirometry quality goals include FEV1 repeatability within 150mL. Between 80% and 90% of tests done by experienced technologists meet these goals, demonstrating that the standards are realistic. Obtaining good quality spirometry tests at each exam is essential when comparing the results from one visit to the next to determine if a clinically-important change in lung function has occurred due to treatment (or disease progression). However, when the results will be used only to determine the presence or absence of clinically-important airway obstruction – as when screening for COPD in smokers – tests with suboptimal quality can still be useful in some cases. For example, even if all of the manoeuvres stop too soon (causing the FVC to be under-reported), when the FEV1 is within the normal range COPD is ruled out (but not asthma). When a pocket spirometer or peak expiratory flow (PEF) meter is used in the first stage of COPD screening, poor quality manoeuvres may cause a falsely low FEV1 or PEF, but these results are not used to make a diagnosis. Instead, the low *Paul Enright